Home The Word Brain My Amedeo FAQ Privacy About   


2049 Chinese

The 20K Word Road to Mandarin Proficiency

By B. S. Kamps et al.


  Colorectal Neoplasms

  Free Subscription


Articles published in Anticancer Res

Retrieve available abstracts of 189 articles:
HTML format



Single Articles


    March 2024
  1. ZHENG W, Chen K, Lv Y, Lao W, et al
    Pyrvinium Pamoate Induces Cell Apoptosis and Autophagy in Colorectal Cancer.
    Anticancer Res. 2024;44:1193-1199.
    PubMed     Abstract available


  2. EBATA Y, Nakanishi R, Tanaka Y, Kawazoe T, et al
    Neoadjuvant Chemotherapy in Patients With T4b or Obstructive Colon Cancer: A Single Center Retrospective Cohort Study.
    Anticancer Res. 2024;44:1281-1287.
    PubMed     Abstract available


  3. HARA S, Sakai D, Ikemura K, Shintani T, et al
    Comparative Efficacy and Safety of Standard and Biweekly Trifluridine/Tipiracil Regimen in Patients With Colorectal Cancer.
    Anticancer Res. 2024;44:1219-1226.
    PubMed     Abstract available


  4. SILVA EF, Fernandes BN, Marinello P, Deminice R, et al
    Pre and Post-high-intensity Interval Training Delays Colon Tumor Onset in a Syngeneic Mouse Model.
    Anticancer Res. 2024;44:1209-1217.
    PubMed     Abstract available


  5. HEGEDUS D, Szemeredi N, Gabor M, Sas J, et al
    Cyclic Amines Coupled to Indole Derivatives With Improved Efflux Pump Inhibiting Activity in Bacteria and Cancer Cells.
    Anticancer Res. 2024;44:1149-1160.
    PubMed     Abstract available


  6. ARDJMAND D, Kubota Y, Sato M, Han Q, et al
    Selective Synergy of Rapamycin Combined With Methioninase on Cancer Cells Compared to Normal Cells.
    Anticancer Res. 2024;44:929-933.
    PubMed     Abstract available


    February 2024
  7. OGAWA H, Shiraishi T, Okada T, Miyamae Y, et al
    Adjuvant Chemotherapy With UFT/LV Versus UFT/LV Plus PSK in Stage II/III Colorectal Cancer.
    Anticancer Res. 2024;44:805-814.
    PubMed     Abstract available


  8. NAKAMURA S, Kageyama H, Torii K, Hishida M, et al
    High-risk Features for Recurrence in Patients With Stage III Colorectal Cancer: A Retrospective Cohort Study.
    Anticancer Res. 2024;44:757-766.
    PubMed     Abstract available


  9. NONAKA K, Nakanishi R, Nambara S, Jiang HQ, et al
    Clinicopathological Impact of High Preoperative CA19-9 in Early-stage Colorectal Cancer: A Single-center Retrospective Cohort Study.
    Anticancer Res. 2024;44:797-803.
    PubMed     Abstract available


  10. ZHENG H, Tsunedomi R, Xu M, Zhang Y, et al
    Effect of Paxillin Expression and Phosphorylation on Colorectal Cancer Prognosis and Metastasis.
    Anticancer Res. 2024;44:511-520.
    PubMed     Abstract available


  11. YAMAMOTO A, Shimizu H, Takiguchi K, Shoda K, et al
    The Expression and Role of Aquaporin 4 in Colon Cancer.
    Anticancer Res. 2024;44:567-573.
    PubMed     Abstract available


  12. NAKAYAMA T, Furuya S, Higuchi Y, Matsuoka K, et al
    Investigating Cytoglobin Expression in Colon Cancer: Clinicopathological Insights from Immunohistochemical Analysis.
    Anticancer Res. 2024;44:561-565.
    PubMed     Abstract available


  13. KOBAYASHI Y, Uemura M, Paku M, Kitakaze M, et al
    Venous Thromboembolism Following Lateral Lymph Node Dissection for Rectal Cancer.
    Anticancer Res. 2024;44:695-701.
    PubMed     Abstract available


  14. KOMORI K, Kinoshita T, Sato Y, Ouchi A, et al
    Novel Repair Technique for Oral and Anal Side Stoma Prolapse of a Loop Colostomy With the Stapled Modified Altemeier Method Using Indocyanine Green Fluorescence Imaging.
    Anticancer Res. 2024;44:853-857.
    PubMed     Abstract available


  15. KE TW, Zwane ST, Chiang SF, Chen TW, et al
    Prognostic Value of Immune Cells Subsets Within the Tumor Microenvironment in Patients With Rectal Adenocarcinoma.
    Anticancer Res. 2024;44:787-796.
    PubMed     Abstract available


  16. IMAOKA K, Ohira M, Shimomura M, Hattori M, et al
    Effect of Abdominal Aortic Calcification on Recurrence Following Initial Hepatectomy for Colorectal Liver Metastases.
    Anticancer Res. 2024;44:649-658.
    PubMed     Abstract available


    January 2024
  17. KIM JH, Cha Y, Shin SJ, Park YS, et al
    Treatment Patterns and Prognosis of Palliative Chemotherapy Combined With Targeting Agents in Patients With Unresectable Metastatic Colorectal Cancer: CHOICE, A Multicenter Longitudinal Observational Study.
    Anticancer Res. 2024;44:347-359.
    PubMed     Abstract available


  18. NAKANISHI T, Matsuda T, Yamashita K, Hasegawa H, et al
    Alb-dNLR Score as a Novel Prognostic Marker for Patients With Locally Advanced Rectal Cancer Undergoing Neoadjuvant Chemoradiotherapy.
    Anticancer Res. 2024;44:229-237.
    PubMed     Abstract available


  19. SATO M, Han Q, Kubota Y, Baranov A, et al
    Recombinant Methioninase Decreased the Effective Dose of Irinotecan by 15-fold Against Colon Cancer Cells: A Strategy for Effective Low-toxicity Treatment of Colon Cancer.
    Anticancer Res. 2024;44:31-35.
    PubMed     Abstract available


  20. LIM YJ, Kong M
    Role of Radical Surgery Following Preoperative Chemoradiotherapy in Octogenarians With Rectal Cancer: A SEER Analysis.
    Anticancer Res. 2024;44:417-425.
    PubMed     Abstract available


  21. JIANG M, Liu Y, Xu J, Xu Z, et al
    Identification and Validation of the Glycolysis and Immune-related Gene Signature for Prognosis in Colorectal Cancer.
    Anticancer Res. 2024;44:117-131.
    PubMed     Abstract available


  22. ESKELINEN M, Meklin J, Guimaraes DP, Selander T, et al
    The Diagnostic Accuracy (DA) of ColonView Fecal Immunochemical Test (FIT) in Detecting Colorectal Adenoma (CRA) Can Be Improved by the Diagnostic Models (DM) that Include Triage and Risk Features of CRA.
    Anticancer Res. 2024;44:173-184.
    PubMed     Abstract available


  23. GOSHIMA T, Ieguchi K, Onishi N, Shimizu T, et al
    Non-classical Monocytes Enhance the Efficacy of Immune Checkpoint Inhibitors on Colon Cancer in a Syngeneic Mouse Model.
    Anticancer Res. 2024;44:23-29.
    PubMed     Abstract available


    December 2023
  24. MATSUBARA D, Soga K, Ikeda J, Konishi T, et al
    Laparoscopic Surgery for Elderly Colorectal Cancer Patients With High American Society of Anesthesiologists Scores.
    Anticancer Res. 2023;43:5637-5644.
    PubMed     Abstract available


  25. ESKELINEN M, Meklin J, Guimaraes DP, Selander T, et al
    Triage Process at Endoscopy With ColonView Fecal Immunochemical Test (FIT) Will Enhance Diagnostic Accuracy (DA) of Colorectal Cancer Screening.
    Anticancer Res. 2023;43:5535-5544.
    PubMed     Abstract available


  26. KUBOYAMA YU, Ishizaki T, Mazaki J, Kasahara K, et al
    Three-dimensional Computed Tomography Evaluation of the Vasculature of Right-side Colon Cancer.
    Anticancer Res. 2023;43:5621-5628.
    PubMed     Abstract available


  27. KOBAYASHI A, Ikemura K, Wakai E, Kondo M, et al
    Proton Pump Inhibitors Ameliorate Oxaliplatin-induced Peripheral Neuropathy: Retrospective Analysis of Two Real-world Clinical Databases.
    Anticancer Res. 2023;43:5613-5620.
    PubMed     Abstract available


  28. KE TW, Chang SC, Liao YM, Lin CH, et al
    Neoadjuvant Chemotherapy With/Without Radiotherapy for Locally Advanced Rectal Cancer: A Nationwide Retrospective Cohort Study.
    Anticancer Res. 2023;43:5713-5722.
    PubMed     Abstract available


  29. TANIGUCHI SH, Komine K, Takenaga N, Yoshida Y, et al
    FOLFIRI Chemotherapy for Patients With Metastatic Urachal Carcinoma.
    Anticancer Res. 2023;43:5699-5704.
    PubMed     Abstract available


  30. WANG L, Cai X, Chen Y, Hirano Y, et al
    Should pT2N+ Colorectal Cancer Be Downstaged from IIIA to IIA?
    Anticancer Res. 2023;43:5681-5688.
    PubMed     Abstract available


  31. TERAISHI F, Shigeyasu K, Kondo Y, Kagawa S, et al
    Clinical Impact of Prehabilitation on Elective Laparoscopic Surgery in Frail Octogenarians With Colorectal Cancer.
    Anticancer Res. 2023;43:5597-5604.
    PubMed     Abstract available


  32. NAKAJO S, Uemura M, Sekido Y, Hata T, et al
    Laparoscopic Colorectal Cancer Surgery for Patients With Severe Chronic Heart Failure.
    Anticancer Res. 2023;43:5645-5648.
    PubMed     Abstract available


  33. LIN HW, Shih TW, Amanna A, Chang MS, et al
    PHRF1 Promotes Cell Invasion by Modulating SOX4 Expression in Colorectal Cancer HCT116-p53(-/-) Cells.
    Anticancer Res. 2023;43:5437-5446.
    PubMed     Abstract available


  34. ZHANG XW, Mohr J, Halama N, Koschny R, et al
    Analysis of an Unselected Patient Cohort With Advanced Colorectal Carcinoma from a Maximum Care Center.
    Anticancer Res. 2023;43:5589-5596.
    PubMed     Abstract available


    November 2023
  35. YOSHIDA T, Homma S, Ichikawa N, Fujiyoshi S, et al
    Feasibility of Laparoscopic and Robotic Total Proctocolectomy for Ulcerative Colitis-related Colorectal Cancer.
    Anticancer Res. 2023;43:5245-5252.
    PubMed     Abstract available


  36. WU CC, Su CC, Chen YH, Hsu CW, et al
    Comparative Effectiveness of Cetuximab Versus Panitumumab in Patients With Metastatic Colorectal Cancer: A Nationwide Database Study.
    Anticancer Res. 2023;43:5127-5138.
    PubMed     Abstract available


  37. RUBIO CA, Matek C, Vieth M, Lang-Schwarz C, et al
    Sporadic Colorectal Tubular Adenomas Thrive in Symbiosis With Underlying Nondysplastic Branching Crypts.
    Anticancer Res. 2023;43:4947-4952.
    PubMed     Abstract available


  38. MIZUUCHI Y, Tanabe Y, Nagayoshi K, Tamura K, et al
    Revisiting the Prognostic Impact of Family History in Colorectal Cancer by Retrospective Propensity Score Matching.
    Anticancer Res. 2023;43:5167-5172.
    PubMed     Abstract available


  39. TAKIGUCHI N, Uemura M, Kitakaze M, Paku M, et al
    High Level Sacral Bone Resection for Locally Recurrent Rectal Cancer.
    Anticancer Res. 2023;43:5061-5066.
    PubMed     Abstract available


  40. HUANG YN, Chen SC, Chen JC, Liu KW, et al
    Elucidating the Cancer Phenotype in Turner Syndrome: A 20-Year Observational Cohort Study.
    Anticancer Res. 2023;43:5073-5081.
    PubMed     Abstract available


  41. MYUNG DS, Oh HH, Kim JS, Lim JW, et al
    Cytochrome P450 Family 46 Subfamily A Member 1 Promotes the Progression of Colorectal Cancer by Inducing Tumor Cell Proliferation and Angiogenesis.
    Anticancer Res. 2023;43:4915-4922.
    PubMed     Abstract available


  42. YAMAMOTO S, Fujii H, Murayama K, Iihara H, et al
    Efficacy and Safety of Oxaliplatin-based Regimens as First-line Chemotherapy in Elderly Patients With Metastatic Colorectal Cancer.
    Anticancer Res. 2023;43:5099-5105.
    PubMed     Abstract available


    October 2023
  43. CHUSANGNIN P, Muangthong T, Payuhakrit W, Palipoch S, et al
    Vitamin C Improves the Inhibitory Effects of Oxaliplatin on HCT-116 Colorectal Cancer Growth and Progression Through Cellular Oxidant Function-associated Cadherin Molecules.
    Anticancer Res. 2023;43:4461-4472.
    PubMed     Abstract available


  44. GARRETT C, Cristaudo A, Barat S, Morris DL, et al
    Increased Incidence of Liver Metastases in Colorectal Versus Appendiceal Adenocarcinoma Peritonectomy Patients Despite Equivocal Survival.
    Anticancer Res. 2023;43:4657-4662.
    PubMed     Abstract available


  45. KATAOKA M, Kitazawa M, Nakamura S, Koyama M, et al
    Cetuximab Enhances the Efficacy of MRTX1133, a Novel KRAS(G12D) Inhibitor, in Colorectal Cancer Treatment.
    Anticancer Res. 2023;43:4341-4348.
    PubMed     Abstract available


  46. ARIMA K, Uemura N, Tsuneyoshi K, Fujita H, et al
    Microsatellite Instability-high Signet Ring Cell Carcinoma of the Colon Treated With Immunotherapy: Report of a Case.
    Anticancer Res. 2023;43:4729-4733.
    PubMed     Abstract available


    September 2023
  47. KIKUCHI R, Sasaki K, Nozawa H, Murono K, et al
    Prognosis of Inferior Mesenteric and Para-aortic Lymph Node Metastases in Rectal Cancer: A Multicenter Study.
    Anticancer Res. 2023;43:4213-4219.
    PubMed     Abstract available


  48. SONG B, Wang L, Chen Y, Hirano Y, et al
    The Significance of Skip Lymph Node Metastasis in Colorectal Cancer.
    Anticancer Res. 2023;43:4169-4177.
    PubMed     Abstract available


  49. OZAKI K, Sasaki K, Abe H, Nozawa H, et al
    Apoptosis-related Prognostic Factors in Advanced Colorectal Cancer Determined Using Tissue Microarrays.
    Anticancer Res. 2023;43:3935-3942.
    PubMed     Abstract available


  50. MINOJI T, Takahashi H, Watabe T, Ishikawa S, et al
    The Clinical Potential of FBPA-PET/CT Imaging for Colorectal Cancer and its Liver Metastases Expressing LAT1.
    Anticancer Res. 2023;43:3913-3921.
    PubMed     Abstract available


  51. ROSENBROCK J, Lieser A, Ostermann-Myrau J, Judge M, et al
    Efficacy and Toxicity of Robotic Stereotactic Body Radiotherapy of Lung Metastases in Patients With Oligometastatic Disease.
    Anticancer Res. 2023;43:4125-4131.
    PubMed     Abstract available


  52. DENG Y, Ke TW, Wang YC, Chin YT, et al
    Impact of Matrix Metalloproteinase-8 Genotypes on Colorectal Cancer Risk in Taiwan.
    Anticancer Res. 2023;43:3979-3985.
    PubMed     Abstract available


    August 2023
  53. MUKOHYAMA J, Agawa K, Yamashita K, Matsuda T, et al
    CDX2 Is a Prognostic Biomarker for Unresectable Metastatic Colorectal Cancer.
    Anticancer Res. 2023;43:3763-3767.
    PubMed     Abstract available


  54. BARAT S, Wijayawardana R, Morris D
    Outcomes for Colorectal Cancer Cases With Peritoneal Metastases Treated With Cytoreductive Surgery With or Without Hyperthermic Intraperitoneal Chemotherapy: A Comparative Analysis of Survival Between Peritoneal Carcinomatosis Scores - PCI in a Single
    Anticancer Res. 2023;43:3529-3538.
    PubMed     Abstract available


  55. NAKANE H, Sudo T, Kawahara A, Yomoda T, et al
    Simplified and Optimized Immune Score for Colorectal Cancer Microenvironment.
    Anticancer Res. 2023;43:3793-3798.
    PubMed     Abstract available


  56. KATAGIRI M, Sudo T, Tounann T, Kakuma T, et al
    Development of an Algorithm to Predict Recurrences After Resection of Liver Metastases in Patients With Metastatic Colorectal Cancer.
    Anticancer Res. 2023;43:3807-3816.
    PubMed     Abstract available


  57. ISHIKAWA T, Imai M, Sato R, Jimbo R, et al
    Prognostic Value of TACE With Irinotecan-loaded Drug-eluting Beads (DEBIRI) in Patients With Liver Metastases from Unresectable Colorectal Cancer.
    Anticancer Res. 2023;43:3647-3651.
    PubMed     Abstract available


  58. YOSHIMITSU K, Mori S, Tanabe K, Wada M, et al
    Transanal Total Mesorectal Excision Considering the Embryology Along the Fascia in Rectal Cancer Patients.
    Anticancer Res. 2023;43:3597-3605.
    PubMed     Abstract available


  59. YOSHIDA K, Nishi K, Ishikura S, Matsumoto T, et al
    Inhibitory Effect of Pyra-Metho-Carnil on Cancer Spheroid Growth Through Decrease in Glycolysis-associated Molecules.
    Anticancer Res. 2023;43:3717-3726.
    PubMed     Abstract available


  60. ESKELINEN M, Meklin J, Guimaraes DP, Selander T, et al
    Fecal Immunochemical Test (FIT) in Triage of Bleed-positive (Crab+) and Bleed-negative Colorectal Adenoma (Crab-) Patients in Colorectal Neoplasia Screening.
    Anticancer Res. 2023;43:3517-3528.
    PubMed     Abstract available


  61. SUGIMOTO K, Takahashi H, Yuki 2nd, Irie T, et al
    Positive Circumferential Resection Margin in Rectal Cancer Is a Robust Predictor of Poor Long-term Prognosis With Clinicopathological Bias Between Groups Compensated by Propensity-score Matching Analysis.
    Anticancer Res. 2023;43:3623-3630.
    PubMed     Abstract available


  62. HIRAKAWA H, Sakai H, Kanno H, Goto Y, et al
    Significance of Desmoplastic Histopathological Growth Pattern for Colorectal Liver Metastases Treated With Preoperative Chemotherapy.
    Anticancer Res. 2023;43:3727-3733.
    PubMed     Abstract available


    July 2023
  63. ISHIZAKI T, Mazaki J, Kasahara K, Udo R, et al
    Learning Curve of Intracorporeal Anastomosis in Laparoscopic Colectomy for Right Side Colon Cancer: A Cumulative Sum Analysis.
    Anticancer Res. 2023;43:3341-3348.
    PubMed     Abstract available


  64. YOSHIMATSU K, Kono T, Satake M, Ito Y, et al
    Poor Prognosis in Patients With Stage III Colorectal Cancer Receiving Adjuvant FOLFOX/CAPOX Therapy Is Predicted by the Presence of Many Poorly Differentiated Clusters.
    Anticancer Res. 2023;43:3235-3240.
    PubMed     Abstract available


  65. MAYANAGI S, Oba K, Aoyama T, Tanaka K, et al
    Feasibility and Safety of Adjuvant Chemotherapy for Resected Colorectal Cancer in Patients With Renal Insufficiency: A Pooled Analysis of Individual Patient Data from Five Japanese Large-scale Clinical Trials.
    Anticancer Res. 2023;43:3089-3095.
    PubMed     Abstract available


  66. KAWASHIMA J, Yamagishi S, Mori K
    Usefulness of 3D-CT Angiography to Determine the Extent of Lymphadenectomy in Colon Cancer of the Splenic Flexure.
    Anticancer Res. 2023;43:3295-3303.
    PubMed     Abstract available


  67. ZOR DS, Hakan MT, Ozgur E, Horozoglu C, et al
    Plasma Levels of Kynurenine, Soluble OX40 and Mir-138-5p Are Associated With Tumor-infiltrating Lymphocytes in Colorectal Cancer: An Exploratory Study.
    Anticancer Res. 2023;43:3281-3288.
    PubMed     Abstract available


  68. YOSHIDA D, Sugiyama M, Nakazono K, Oyama T, et al
    Oncological Impact of the Level of Inferior Mesenteric Artery Ligation in Low Rectal Cancer Surgery.
    Anticancer Res. 2023;43:3225-3233.
    PubMed     Abstract available


  69. SHIRAISHI T, Ogawa H, Yamaguchi A, Shioi I, et al
    Two-team Total Mesorectal Excision and Lateral Pelvic Lymph Node Dissection Using Transanal Approach for Rectal Cancer: A Retrospective Study.
    Anticancer Res. 2023;43:3311-3319.
    PubMed     Abstract available


  70. TAN CQY, Ho A, Robinson HA, Huang L, et al
    A Systematic Review of Microwave Ablation for Colorectal Pulmonary Metastases.
    Anticancer Res. 2023;43:2899-2907.
    PubMed     Abstract available


    June 2023
  71. YUN CW, Lee JH, Lee SH
    Casein Kinase 2alpha Augments Oxaliplatin Resistance in Colorectal Cancer Cells by Increasing ABCE1 Expression.
    Anticancer Res. 2023;43:2519-2525.
    PubMed     Abstract available


  72. LA FRANCA A, Muttillo EM, Madaffari I, Massimi F, et al
    Lymph Node Metastasis in Extraperitoneal Rectal Cancer After Neoadjuvant Therapy: An Unsolved Problem?
    Anticancer Res. 2023;43:2813-2820.
    PubMed     Abstract available


  73. TAKIGUCHI K, Shimizu H, Shoda K, Shiraishi K, et al
    The Expression and Role of NADPH Oxidase 2 in Colon Cancer.
    Anticancer Res. 2023;43:2601-2608.
    PubMed     Abstract available


  74. TAKAKUSAGI Y, Koge H, Kano K, Shima S, et al
    Safety of Carbon-ion Radiotherapy for Prostate Cancer After Rectal Cancer Surgery.
    Anticancer Res. 2023;43:2691-2695.
    PubMed     Abstract available


  75. AKAGI H, Tanaka Y, Wada K, Takahashi M, et al
    CDX2-positive Cancer of Unknown Primary With Upper-body Paralysis Was Dramatically Improved by Colorectal Cancer Chemotherapy.
    Anticancer Res. 2023;43:2879-2884.
    PubMed     Abstract available


  76. HAYASHI K, Furuta M, Furusawa K, Hamaguchi T, et al
    Evaluation of Irinotecan and Trifluridine/Tipiracil as Fourth-line Treatments After Third-line Nivolumab for Advanced Gastric Cancer.
    Anticancer Res. 2023;43:2831-2840.
    PubMed     Abstract available


    May 2023
  77. KIM IS, Cho SY, Yang M, Han S, et al
    ATG9B Is a Poor Prognostic Marker Associated With Immune Evasion in Colon Adenocarcinoma.
    Anticancer Res. 2023;43:1943-1957.
    PubMed     Abstract available


  78. NAKAGAWA R, Kumamoto T, Maeda F, Tani K, et al
    New Scale Predicting Distant Recurrence in Locally Advanced Lower Rectal Cancer Patients After Neoadjuvant Chemoradiotherapy.
    Anticancer Res. 2023;43:2179-2184.
    PubMed     Abstract available


  79. MIYASHITA S, Shimizu T, Ishizuka M, Niki M, et al
    N2 Lymph Node Metastasis Is a Useful Predictor of Recurrence in Patients With Stage III Rectal Cancer Undergoing Adjuvant Chemotherapy Using Tegafur-uracil/leucovorin.
    Anticancer Res. 2023;43:2219-2225.
    PubMed     Abstract available


  80. HUANG CI, Huang YK, Lee HM, Chen JH, et al
    Synergistic and Antagonistic Antiproliferative Effects of Ribociclib (Lee011) and Irinotecan (SN38) on Colorectal Cancer Cells.
    Anticancer Res. 2023;43:1933-1941.
    PubMed     Abstract available


  81. MATSUOKA S, Fujii H, Iihara H, Ohata K, et al
    Emetogenicity and Risk Factors of Nausea and Vomiting in Patients With Metastatic Colorectal Cancer Receiving Trifluridine/Tipiracil and Bevacizumab Chemotherapy.
    Anticancer Res. 2023;43:2351-2357.
    PubMed     Abstract available


  82. RYU S, Kitagawa T, Goto K, Nagashima A, et al
    Transanal Total Mesorectal Excision for Extended Surgery in the Early Stage After Introduction.
    Anticancer Res. 2023;43:2211-2217.
    PubMed     Abstract available


  83. NAKAI N, Maeda A, Yanagita T, Suzuki T, et al
    Elevated Preoperative Serum Vascular Endothelial Growth Factor Does Not Predict Poor Outcomes in Curatively Resected Non-metastatic Colorectal Cancer Treated Without Neoadjuvant Therapy.
    Anticancer Res. 2023;43:2333-2341.
    PubMed     Abstract available


  84. FUKUDA S, Niisato Y, Tsuji M, Fukuda S, et al
    Relationship Between Safety and Cumulative Bevacizumab Dose in Patients With Metastatic Colorectal Cancer Who Received Long-term Bevacizumab Treatment.
    Anticancer Res. 2023;43:2085-2090.
    PubMed     Abstract available


  85. ORLANDI E, Romboli A, Citterio C, Trubini S, et al
    Prognostic Impact of Ras Mutation on Surgical Strategy in Rectal Cancer Patients Undergoing Neoadjuvant Treatment.
    Anticancer Res. 2023;43:2015-2024.
    PubMed     Abstract available


    April 2023
  86. SATO K, Kasajima H, Imaizumi K, Kurushima M, et al
    Visualization of Anorectal Lymphatic Flow Using Indocyanine Green Fluorescence Imaging: An Observational Study.
    Anticancer Res. 2023;43:1591-1598.
    PubMed     Abstract available


  87. DORMAN K, Zhang D, Kunz WG, Angele M, et al
    Treatment of Mediastinal Endometrial Carcinoma Developed from Extragenital Endometriosis and Simultaneous Rectal Adenocarcinoma in a 55-year-old Woman.
    Anticancer Res. 2023;43:1857-1861.
    PubMed     Abstract available


  88. CHINCZEWSKI L, Feldhaus FW, Schmitt W, Braicu I, et al
    Complete Response to Immune Checkpoint Inhibition in a Platinum Resistant Primary Ovarian Cancer Patient With Lynch Syndrome: A Case Report and Review of the Literature.
    Anticancer Res. 2023;43:1655-1662.
    PubMed     Abstract available


  89. KE TW, Chang SC, Chen HC, Wang HM, et al
    Pelvic Neoadjuvant Radiotherapy for Stage M1a Rectal Adenocarcinoma Patients Treated With Systemic Therapy Followed by Proctectomy and Metastasectomy: A Nationwide Retrospective Cohort Study.
    Anticancer Res. 2023;43:1843-1851.
    PubMed     Abstract available


  90. BYUN J, Park NJ, Yoon G, Kang MK, et al
    PIK3CA Mutations as a Prognostic Factor in Patients With Residual Rectal Cancer After Neoadjuvant Chemoradiotherapy.
    Anticancer Res. 2023;43:1513-1520.
    PubMed     Abstract available


  91. ASAKO K, Hayama T, Hashiguchi Y, Miyata T, et al
    Prognostic Value of KRAS Exon-specific Mutations in Patients With Colorectal Cancer.
    Anticancer Res. 2023;43:1563-1568.
    PubMed     Abstract available


  92. KIM H, Kim HS
    Mesonephric-like Adenocarcinoma of the Uterine Corpus: Comparison Between Mismatch Repair Protein Immunostaining and Microsatellite Instability Testing.
    Anticancer Res. 2023;43:1785-1795.
    PubMed     Abstract available


  93. ESKELINEN M, Meklin J, Guimaraes DP, Selander T, et al
    Diagnostic Accuracy of Fecal Immunochemical Test (FIT) in Bleed-positive and Bleed-negative Colorectal Cancer (CRC) Among a Cohort of 5,090 Subjects who Participated in the Colorectal Neoplasia (CRN) Screening in Brazil.
    Anticancer Res. 2023;43:1569-1580.
    PubMed     Abstract available


    March 2023
  94. KOBUCHI S, Tsuda M, Okamura M, Nakamura T, et al
    A Pharmacokinetic-Pharmacodynamic Model Predicts Uracil-tegafur Effect on Tumor Shrinkage and Myelosuppression in a Colorectal Cancer Rat Model.
    Anticancer Res. 2023;43:1121-1130.
    PubMed     Abstract available


    February 2023
  95. XU M, Tsunedomi R, Kiyotani K, Tomochika S, et al
    Anti-VEGF and Anti-EGFR Antibody Therapy on T-Cell Infiltration and TCR Variation in Metastatic Colorectal Cancer.
    Anticancer Res. 2023;43:613-620.
    PubMed     Abstract available


  96. PAIAR F, Gabelloni M, Pasqualetti F, Cocuzza P, et al
    Correlation of Pre- and Post-radio-chemotherapy MRI Texture Features With Tumor Response in Rectal Cancer.
    Anticancer Res. 2023;43:781-788.
    PubMed     Abstract available


  97. FERRARI C, Cuniolo L, Mascherini M, Santoliquido M, et al
    Pelvic Recurrence After Curative Resection for Rectal Adenocarcinoma: Impact of Surgery on Survival.
    Anticancer Res. 2023;43:765-771.
    PubMed     Abstract available


  98. WEBER F, Jung R, Treeck O, Buechler C, et al
    Chemerin and Chemokine-like Receptor 1 Are Not Prognostic in Colorectal Carcinoma.
    Anticancer Res. 2023;43:831-839.
    PubMed     Abstract available


    January 2023
  99. SHIRAISHI T, Ogawa H, Yamaguchi A, Saito H, et al
    Relationship Between C-reactive Protein-to-albumin Ratio Before and After Bowel Decompression and Prognosis in Acute Malignant Large Bowel Obstruction.
    Anticancer Res. 2023;43:259-267.
    PubMed     Abstract available


  100. BRENNER B, Stern Y, Gordon N, Fuks T, et al
    Differences in Toxicity Between Ashkenazi and Sephardic Jews With Colon Cancer Treated With Adjuvant Chemotherapy: A Prospective Study.
    Anticancer Res. 2023;43:239-245.
    PubMed     Abstract available


  101. CHIDIMATSU H, Tsunedomi R, Nakagami Y, Xu M, et al
    Serum CCL7 Is a Novel Prognostic Biomarker of Metastatic Colorectal Cancer.
    Anticancer Res. 2023;43:105-114.
    PubMed     Abstract available


  102. PISTOLESI S, Fanelli GN, Giudice F, Garbini F, et al
    Cervical Adenocarcinoma: A Still Under-investigated Malignancy.
    Anticancer Res. 2023;43:53-58.
    PubMed     Abstract available


  103. KIM MJ, Han Q, Bouvet M, Hoffman RM, et al
    Recombinant Oral Methioninase (o-rMETase) Combined With Oxaliplatinum Plus 5-Fluorouracil Improves Survival of Mice With Massive Colon-Cancer Peritoneal Carcinomatosis.
    Anticancer Res. 2023;43:19-24.
    PubMed     Abstract available


    December 2022
  104. HAYASE S, Miyoshi N, Fujino S, Yasui M, et al
    Fibroblast Activation Protein and Tertiary Lymphoid Structure in Colorectal Cancer Recurrence.
    Anticancer Res. 2022;42:5897-5907.
    PubMed     Abstract available


  105. LIM S, Kawai K, Nozawa H, Sasaki K, et al
    Low Expression of SNAI1 in Lymph Node Metastasis Indicates Delayed Recurrence of Colonic Cancer.
    Anticancer Res. 2022;42:5927-5935.
    PubMed     Abstract available


  106. RUBIO CA, Lang-Schwarz C, Vieth M
    Further Study on Field Cancerization in the Human Colon.
    Anticancer Res. 2022;42:5891-5895.
    PubMed     Abstract available


    November 2022
  107. DOI H, Fujiwara M, Beppu N, Yokoyama H, et al
    Neoadjuvant Modified Short-course Radiotherapy for Stage IV Rectal Cancer.
    Anticancer Res. 2022;42:5587-5595.
    PubMed     Abstract available


  108. YUEH TC, Hung YC, Lee HT, Yang MD, et al
    Role of Matrix Metallopeptidase-2 Genotypes in Taiwanese Patients With Colorectal Cancer.
    Anticancer Res. 2022;42:5335-5342.
    PubMed     Abstract available


  109. YAMAUCHI N, Matsuda T, Sawad R, Hasegawa H, et al
    Clinical Significance of Early Recurrence After Curative Resection of Colorectal Cancer.
    Anticancer Res. 2022;42:5553-5559.
    PubMed     Abstract available


  110. TAKEDA K, Kikuchi Y, Sawada YU, Kumamoto T, et al
    Efficacy of Adjuvant Chemotherapy Following Curative Resection of Colorectal Cancer Liver Metastases.
    Anticancer Res. 2022;42:5497-5505.
    PubMed     Abstract available


  111. PARK YL, Cho SB, Park SY, Oh HH, et al
    Engulfment and Cell Motility 1 (ELMO1) Regulates Tumor Cell Behavior and Predicts Prognosis in Colorectal Cancer.
    Anticancer Res. 2022;42:5343-5355.
    PubMed     Abstract available


  112. MEIROVITZ A, Baider L, Peretz T, Stephanos S, et al
    PTX Treatment of Colon Cancer: Mode of Action Based on Tumor Marker and Cytokine Kinetics.
    Anticancer Res. 2022;42:5487-5496.
    PubMed     Abstract available


  113. TOMINAGA T, Nonaka T, Oyama S, Takamura Y, et al
    Gustave Roussy Immune Score for Predicting Postoperative Complications and Non-cancer Death in Elderly Patients With Colon Cancer.
    Anticancer Res. 2022;42:5643-5653.
    PubMed     Abstract available


  114. KIM SH, Song SE, Baik H, Hur DY, et al
    15-Prostaglandin Dehydrogenase Inhibition Enhances Colon Cancer Metastasis by Up-regulation of Epithelial-to-Mesenchymal Transition Genes.
    Anticancer Res. 2022;42:5385-5396.
    PubMed     Abstract available


    October 2022
  115. KATO S, Miyoshi N, Fujino S, Minami S, et al
    Combined Inflammation and Nutrition Factors Reinforce the Prognostic Prediction for Stage III Colorectal Cancer Patients.
    Anticancer Res. 2022;42:4989-4999.
    PubMed     Abstract available


  116. CHOMICKI S, Chapet S, Drifa M, Ouaissi M, et al
    Outcomes and Side Effects of Preoperative Chemoradiotherapy for Locally Advanced Upper Rectal Cancer.
    Anticancer Res. 2022;42:4833-4840.
    PubMed     Abstract available


  117. OZATO Y, Masuda T, Kobayashi Y, Takao S, et al
    PRKRIP1, A Splicing Complex Factor, Is a Marker of Poor Prognosis in Colorectal Cancer.
    Anticancer Res. 2022;42:4701-4706.
    PubMed     Abstract available


  118. RYU S, Kitagawa T, Goto K, Okamoto A, et al
    Intraoperative Holographic Guidance Using Virtual Reality and Mixed Reality Technology During Laparoscopic Colorectal Cancer Surgery.
    Anticancer Res. 2022;42:4849-4856.
    PubMed     Abstract available


  119. ZHU D, Guo P, Jin XY, Zhang R, et al
    Long-chain Non-coding RNA MIR4435-2HG Expression Correlates With Size of Intestinal Polyps in Children and With Metastasis of Colon Cancer.
    Anticancer Res. 2022;42:4707-4714.
    PubMed     Abstract available


  120. CZAPLA J, Drzyzga A, Matuszczak S, Pilny E, et al
    The Complex Composition of Trans-resveratrol, Quercetin, Vitamin E and Selenium Inhibits the Growth of Colorectal Carcinoma.
    Anticancer Res. 2022;42:4763-4772.
    PubMed     Abstract available


  121. UTSUMI M, Inagaki M, Kitada K, Tokunaga N, et al
    Lymphocyte-to-C-Reactive Protein Ratio Predicts Prognosis in Patients With Colorectal Liver Metastases Post-hepatic Resection: A Retrospective Study.
    Anticancer Res. 2022;42:4963-4971.
    PubMed     Abstract available


  122. GERGER A, Eisterer W, Fuxius S, Bastian S, et al
    Retrospective Analysis of Treatment Pathways in Patients With BRAF(V600E)-mutant Metastatic Colorectal Carcinoma - MORSE(CRC).
    Anticancer Res. 2022;42:4773-4785.
    PubMed     Abstract available


    September 2022
  123. RUBIO CA, Vieth M, Lang-Schwarz C
    Crypts in Asymmetric Branching in Patients With Ulcerative Colitis in Remission.
    Anticancer Res. 2022;42:4493-4497.
    PubMed     Abstract available


  124. TAN C, Fisher OM, Huang L, Alzahrani N, et al
    Comparison of Microwave and Radiofrequency Ablation in the Treatment of Pulmonary Metastasis of Colorectal Cancer.
    Anticancer Res. 2022;42:4563-4571.
    PubMed     Abstract available


  125. CRISTAUDO AT, Jennings SB, Morris DL
    Comparison of Proportion of Elevated Carcinoembryonic Antigen Levels in Patients With Appendiceal and Colorectal Adenocarcinoma: A Systematic Review and Meta-analysis.
    Anticancer Res. 2022;42:4217-4235.
    PubMed     Abstract available


    August 2022
  126. KAWAMURA H, Honda M, Takano Y, Kinuta S, et al
    Prognostic Role of Carcinoembryonic Antigen and Carbohydrate Antigen 19-9 in Stage IV Colorectal Cancer.
    Anticancer Res. 2022;42:3921-3928.
    PubMed     Abstract available


  127. KUBOTA Y, Han Q, Hamada K, Aoki Y, et al
    Long-term Stable Disease in a Rectal-cancer Patient Treated by Methionine Restriction With Oral Recombinant Methioninase and a Low-methionine Diet.
    Anticancer Res. 2022;42:3857-3861.
    PubMed     Abstract available


  128. YOSHIDA K, Nishi K, Ishikura S, Nakabayashi K, et al
    Cancer Spheroid Proliferation Is Suppressed by a Novel Low-toxicity Compound, Pyra-Metho-Carnil, in a Context-independent Manner.
    Anticancer Res. 2022;42:3993-4001.
    PubMed     Abstract available


    July 2022
  129. KATAOKA S, Arita T, Konishi H, Yamamoto Y, et al
    The Role of Inflammation-associated microRNA-4257 as a Promoter of Malignancy in Colorectal Cancer.
    Anticancer Res. 2022;42:3349-3360.
    PubMed     Abstract available


  130. ESKELINEN M, Meklin J, Guimaraes DP, Selander T, et al
    Site-specific Performance of ColonView (CV) Fecal Immunochemical Test (FIT) With Differences Between Proximal and Distal Colorectal Adenoma.
    Anticancer Res. 2022;42:3557-3567.
    PubMed     Abstract available


  131. MINAMI S, Miyoshi N, Fujino S, Kato S, et al
    The Geriatric Nutritional Risk Index as a Prognosis Predictor in Patients With Rectal Cancer Receiving Neoadjuvant Chemotherapy.
    Anticancer Res. 2022;42:3759-3766.
    PubMed     Abstract available


  132. HIRAIDE T, Morita Y, Horikawa M, Sugiyama E, et al
    Saturated Fatty Acids in Cell Membrane Lipids Induce Resistance to 5-Fluorouracil in Colorectal Cancer Cells.
    Anticancer Res. 2022;42:3313-3324.
    PubMed     Abstract available


    June 2022
  133. TOMINAGA T, Nonaka T, Oyama S, Takamura Y, et al
    Utility of Drain Fluid Culture and Gram Stain in Early Intervention for Occult Anastomotic Leakage in Colorectal Cancer.
    Anticancer Res. 2022;42:3091-3098.
    PubMed     Abstract available


  134. OIKONOMAKIS I, Brodin D, Horer TM, Skoog P, et al
    Altered mRNA Expression Due to Rectal Perforation in a Porcine Model - A Pilot Study.
    Anticancer Res. 2022;42:2827-2833.
    PubMed     Abstract available


    May 2022
  135. WU MH, Chen CH, Chen CP, Huang TL, et al
    Contribution of 5-Methyltetrahydrofolate-Homocysteine Methyltransferase Reductase Genotypes to Colorectal Cancer in Taiwan.
    Anticancer Res. 2022;42:2375-2382.
    PubMed     Abstract available


  136. TAMAGAWA H, Aoyama T, Numata M, Kazama K, et al
    Impact of Infectious Complications on Survival and Recurrence of Patients With Stage II/III Colorectal Cancer: A Multicenter Retrospective Study.
    Anticancer Res. 2022;42:2763-2769.
    PubMed     Abstract available


  137. SATO S, Mikayama YO, Shiozawa M, Nukada S, et al
    Chemotherapy-induced Reversion of Mutant RAS to Wild-type RAS in Metastatic Colorectal Cancer.
    Anticancer Res. 2022;42:2625-2635.
    PubMed     Abstract available


  138. SONODA H, Kitamura C, Kano K, Anzai H, et al
    Changes in Lysophospholipid Components in Ulcerative Colitis and Colitis-associated Cancer.
    Anticancer Res. 2022;42:2461-2468.
    PubMed     Abstract available


  139. TANIOKA H, Shimada K, Tsuji A, Kochi M, et al
    Phase II Study of S-1 and Irinotecan Plus Bevacizumab as Second-line Treatment for Patients With Metastatic Colorectal Cancer Resistant to the Fluoropyrimidine-oxaliplatin-cetuximab Regimen.
    Anticancer Res. 2022;42:2675-2681.
    PubMed     Abstract available


  140. PETRAKIS G, Mantso T, Koukourakis MI, Panayiotidis MI, et al
    Effectiveness of Hyperthermia as Monotherapy and Adjuvant Therapy Approaches Against an In Vitro Model of Colorectal Carcinoma.
    Anticancer Res. 2022;42:2363-2374.
    PubMed     Abstract available


    April 2022
  141. ESKELINEN M, Meklin J, Guimaraes DP, Selander T, et al
    The ColonView (CV) Quick Test for Fecal Occult Blood Shows Significantly Higher Diagnostic Accuracy in Detecting Distal than Proximal Colorectal Cancer.
    Anticancer Res. 2022;42:1879-1891.
    PubMed     Abstract available


  142. KATO A, Miyoshi N, Ohtsuru T, Sakai D, et al
    A Phase II Study of Dose-reductive XELOX Plus Bevacizumab in Elderly or Vulnerable Patients With Metastatic Colorectal Cancer (MCSGO-1202).
    Anticancer Res. 2022;42:1859-1865.
    PubMed     Abstract available


  143. HONG JK, Kim DY, Shin JS, Ryu YS, et al
    CJ14939, a Novel JAK Inhibitor, Increases Oxaliplatin-induced Cell Death Through JAK/STAT Pathway in Colorectal Cancer.
    Anticancer Res. 2022;42:1813-1819.
    PubMed     Abstract available


  144. ISHIZAKI T, Katsumata K, Enomoto M, Mazaki J, et al
    Predictors of Lateral Pelvic Lymph Node Metastasis in Advanced Low Rectal Cancer Treated With Neoadjuvant Chemotherapy.
    Anticancer Res. 2022;42:2113-2121.
    PubMed     Abstract available


  145. TACHIKAWA Y, Kawai K, Ozaki K, Nozawa H, et al
    CD133(+)HIF-1alpha(-) Expression After Chemoradiotherapy Predicts Poor Prognosis in Rectal Cancer.
    Anticancer Res. 2022;42:2033-2043.
    PubMed     Abstract available


  146. TOMITA K, Chiba N, Ochiai S, Gunji T, et al
    Prognostic Impact of N2 of the Primary Tumour in Surgical Resection for Colorectal Liver Metastases.
    Anticancer Res. 2022;42:1997-2001.
    PubMed     Abstract available


  147. KARAM E, Sindayigaya R, Giger-Pabst U, Gabriel M, et al
    Impact of Modern Management Strategies on the Clinical Outcome of Patients With Low Rectal Cancer - A Retrospective, Monocentric Cohort Study.
    Anticancer Res. 2022;42:1949-1963.
    PubMed     Abstract available


    March 2022
  148. MAEDA A, Takahashi H, Harata S, Watanabe K, et al
    The Interaction Between Cancer-associated Fibroblasts and Cancer Cells Enhances Bcl-xL and Mcl-1 in Colorectal Cancer.
    Anticancer Res. 2022;42:1277-1288.
    PubMed     Abstract available


  149. MATSUMURA K, Yamamura K, Miyamoto H, Hara Y, et al
    Highly Advanced Colorectal Liver Metastases Successfully Treated With Fluorouracil Plus Leucovorin Monotherapy and Microwave Ablation.
    Anticancer Res. 2022;42:1645-1651.
    PubMed     Abstract available


  150. MATSUDA R, Kotsugi M, Nakase K, Morimoto T, et al
    Awake Craniotomy for Subcortical Brain Metastasis Beneath the Speech Center: A Technical Case Report.
    Anticancer Res. 2022;42:1641-1644.
    PubMed     Abstract available


  151. KATAYAMA H, Tominaga T, Nonaka T, Araki M, et al
    Effect of Neoadjuvant Chemotherapy in Patients With Locally Advanced Rectal Cancer: A Multicenter Propensity Score-matched Analysis.
    Anticancer Res. 2022;42:1527-1533.
    PubMed     Abstract available


  152. NACARKAHYA G, Borazan E, Horozoglu C, Yaylim I, et al
    Investigation of Long Non-coding RNAs H19 and LINC00675 in Colorectal Cancers in Terms of Histopathological Features and Correlations With Plasma Markers.
    Anticancer Res. 2022;42:1301-1306.
    PubMed     Abstract available


    February 2022
  153. LIANG JA, Kuo YC, Chao KSC, Chen WT, et al
    High vs. Standard Radiotherapy Dose in Locally Advanced Rectal Adenocarcinoma Patients Treated With Neoadjuvant Long Course Chemoradiotherapy: A Population-based Study.
    Anticancer Res. 2022;42:1143-1150.
    PubMed     Abstract available


  154. SHIRAISHI T, Ogawa H, Ozawa N, Suga K, et al
    Risk and Protective Factors for Postoperative Complications in Elderly Patients With Colorectal Cancer.
    Anticancer Res. 2022;42:1123-1130.
    PubMed     Abstract available


  155. TOMIOKA K, Aoki T, Watanabe M, Enami Y, et al
    Increased Transumbilical Incision Complication Rates With Laparoscopic Colorectal Resection: A Single-center Propensity Score-matched Cohort Study.
    Anticancer Res. 2022;42:1115-1121.
    PubMed     Abstract available


  156. DE FELICE F, Musio D, Iafrate F, Caponnetto S, et al
    Intensified Total Neoadjuvant Therapy Versus Intensified Concurrent Chemoradiotherapy in Locally Advanced Rectal Cancer: A Propensity Score Matching Analysis.
    Anticancer Res. 2022;42:991-1000.
    PubMed     Abstract available


  157. KOYAMA M, Osada E, Akiyama N, Eto K, et al
    Effect of Thymidine Phosphorylase Gene Demethylation on Sensitivity to 5-Fluorouracil in Colorectal Cancer Cells.
    Anticancer Res. 2022;42:837-844.
    PubMed     Abstract available


  158. HAGIWARA T, Sugimoto K, Momose H, Irie T, et al
    CHFR-Promoter-Methylation Status Is Predictive of Response to Irinotecan-based Systemic Chemotherapy in Advanced Colorectal Cancer.
    Anticancer Res. 2022;42:697-707.
    PubMed     Abstract available


  159. GO G, Park HJ, Lee JH, Yun CW, et al
    Inhibitory Effect of Oxaliplatin-loaded Engineered Milk Extracellular Vesicles on Tumor Progression.
    Anticancer Res. 2022;42:857-866.
    PubMed     Abstract available


    January 2022
  160. HWANG J, Park A, Kim C, Yu D, et al
    Suppression of DYRK1A/B Drives Endoplasmic Reticulum Stress-mediated Autophagic Cell Death Through Metabolic Reprogramming in Colorectal Cancer Cells.
    Anticancer Res. 2022;42:589-598.
    PubMed     Abstract available


  161. MIYOSHI K, Sato E, Katsumata K, Fukushima G, et al
    CD15(+) Bone Marrow-derived Cells Are Regulators of Immune Response in ARG1-producing Colorectal Cancer Cells.
    Anticancer Res. 2022;42:459-470.
    PubMed     Abstract available


  162. MULLER O, Sindayigaya R, Chomicki S, Karam E, et al
    Prognostic Impact of Upfront Surgery for Locally Advanced Upper Rectal Adenocarcinoma.
    Anticancer Res. 2022;42:155-164.
    PubMed     Abstract available


  163. MIYATA H, Akiyama Y, Iizuka A, Kondou R, et al
    Development of an Automatic Measurement Method for CD8 and PD-1 Positive T Cells Using Image Analysis Software.
    Anticancer Res. 2022;42:419-427.
    PubMed     Abstract available


  164. BRESCIA A, Muttillo EM, Angelicone I, Madaffari I, et al
    The Role of Indocyanine Green in Laparoscopic Low Anterior Resections for Rectal Cancer Previously Treated With Chemo-radiotherapy: A Single-center Retrospective Analysis.
    Anticancer Res. 2022;42:211-216.
    PubMed     Abstract available


    December 2021
  165. SHIBUTANI M, En W, Okazaki Y, Kashiwagi S, et al
    The Efficacy and Safety of Trifluridine/Tipiracil Treatment for Elderly Patients With Metastatic Colorectal Cancer in a Real-world Setting.
    Anticancer Res. 2021;41:6211-6216.
    PubMed     Abstract available


  166. ZENG X, Zhang L, Jia S, Lin T, et al
    Effects of Circulating 25(OH)D Status in Advanced Colorectal Cancer Patients Undergoing Chemotherapy: A Systematic Review.
    Anticancer Res. 2021;41:5903-5912.
    PubMed     Abstract available


  167. MATSUHASHI N, Takahashi T, Tanaka C, Yawata K, et al
    Phase II Study of Preoperative Chemoradiotherapy With S-1 Plus Oxaliplatin for Locally Advanced Rectal Cancer (PerSeUS-RC01).
    Anticancer Res. 2021;41:6247-6257.
    PubMed     Abstract available


    November 2021
  168. MAZAKI J, Katsumata K, Ohno Y, Udo R, et al
    A Novel Predictive Model for Anastomotic Leakage in Colorectal Cancer Using Auto-artificial Intelligence.
    Anticancer Res. 2021;41:5821-5825.
    PubMed     Abstract available


  169. KAWAMURA H, Honda M, Takiguchi K, Kamiga T, et al
    Clinical Impact of Primary Tumor Site in Stage IV Colorectal Cancer: A Statewide Cohort Study.
    Anticancer Res. 2021;41:5693-5702.
    PubMed     Abstract available


  170. TAGO T, Katsumata K, Udou R, Kasahara K, et al
    Significance of Radiofrequency Ablation for Unresectable Colorectal Cancer With Liver Metastases.
    Anticancer Res. 2021;41:5539-5547.
    PubMed     Abstract available


  171. ISHIZAWA M, Hirayu A, Makishima M
    Zinc Inhibits Cadherin 1 Expression Induced by 1alpha,25-Dihydroxyvitamin D3 in Colon Cancer Cells.
    Anticancer Res. 2021;41:5453-5459.
    PubMed     Abstract available


  172. SUZUMURA H, Tsuruta M, Okabayashi K, Shigeta K, et al
    BAF57 Is a Potential Determinant of Colorectal Cancer Malignancy.
    Anticancer Res. 2021;41:5445-5452.
    PubMed     Abstract available


  173. ROH SA, Kwon YH, Lee JL, Kim SK, et al
    SLAMF7 and TREM1 Mediate Immunogenic Cell Death in Colorectal Cancer Cells: Focus on Microsatellite Stability.
    Anticancer Res. 2021;41:5431-5444.
    PubMed     Abstract available


  174. ADACHI Y, Yamamura K, Yumoto S, Higashi T, et al
    Far-advanced Colorectal Liver Metastases Successfully Managed With Modified ALPPS and Radiofrequency Ablation in Combination With Chemotherapy.
    Anticancer Res. 2021;41:5855-5861.
    PubMed     Abstract available


  175. AKAHOSHI S, Yamamura K, Komohara Y, Yoshii D, et al
    A Case Report of Metachronous Multiple Adenosquamous Carcinoma of the Colon Over-expressing PD-L1 and a Literature Review.
    Anticancer Res. 2021;41:5847-5854.
    PubMed     Abstract available


  176. FURUKAWA K, Onda S, Taniai T, Hamura R, et al
    Risk Factors and Overcoming Strategies of Surgical Site Infection After Hepatectomy for Colorectal Liver Metastases.
    Anticancer Res. 2021;41:5651-5656.
    PubMed     Abstract available


  177. MASATSUNE S, Kimura K, Kashiwagi S, En W, et al
    Impact of Intraoperative Blood Loss and Blood Transfusion on the Prognosis of Colorectal Liver Metastasis Following Curative Resection.
    Anticancer Res. 2021;41:5617-5623.
    PubMed     Abstract available


  178. OKAMOTO D, Matsuda T, Sawada R, Hasegawa H, et al
    Risk Factors for Complications Following Lateral Pelvic Lymph Node Dissection for Rectal Cancer.
    Anticancer Res. 2021;41:5599-5604.
    PubMed     Abstract available


  179. MEKLIN J, Eskelinen M, Guimaraes DP, Selander T, et al
    The Automatically Analyzed (AA) ColonView (CV) Quick Test for Fecal Occult Blood Shows Higher Diagnostic Accuracy in Detection of Colorectal Adenoma than Visually Analyzed Tests.
    Anticancer Res. 2021;41:5517-5525.
    PubMed     Abstract available


    October 2021
  180. SATO S, Shiozawa M, Nukada S, Iguchi K, et al
    Preoperative Pre-albumin Concentration as a Predictor of Short-term Outcomes in Elderly Patients With Colorectal Cancer.
    Anticancer Res. 2021;41:5195-5202.
    PubMed     Abstract available


  181. ATSUMI Y, Numata M, Kazama K, Kawahara S, et al
    Can D3 Lymph Node Dissection for Patients With Colon Cancer With a Poor C-Reactive Protein/Albumin Ratio Improve Survival Outcomes?
    Anticancer Res. 2021;41:5097-5106.
    PubMed     Abstract available


  182. MEKLIN J, Eskelinen M, Guimaraes DP, Selander T, et al
    The New Generation Immunochemical Test for Fecal Occult Blood (ColonView Quick Test) Shows a High Diagnostic Accuracy in Colorectal Cancer Detection.
    Anticancer Res. 2021;41:5071-5079.
    PubMed     Abstract available


  183. NEUPANE P, Mimura K, Nakajima S, Okayama H, et al
    The Expression of Immune Checkpoint Receptors and Ligands in the Colorectal Cancer Tumor Microenvironment.
    Anticancer Res. 2021;41:4895-4905.
    PubMed     Abstract available


  184. TADA Y, Matsumi Y, Hara K, Miyauchi W, et al
    Infiltration of CD204-overexpressing Macrophages Contributes to the Progression of Stage II and III Colorectal Cancer.
    Anticancer Res. 2021;41:4857-4865.
    PubMed     Abstract available


  185. MIYAMOTO S, Fukui T, Horitani S, Tanimura Y, et al
    Linker Threonine-phosphorylated Smad2/3 Is a Biomarker of Colorectal Neoplastic Stem-like Cells that Correlates With Carcinogenesis.
    Anticancer Res. 2021;41:4789-4799.
    PubMed     Abstract available


  186. OZLUK E, Coppola D, Mohammad IZ, Islam T, et al
    Ethylmalonic Encephalopathy 1 Protein Is Increased in Colorectal Adenocarcinoma.
    Anticancer Res. 2021;41:4719-4723.
    PubMed     Abstract available


  187. SATO K, Miura T, Sakamoto Y, Morohashi H, et al
    Fascial Organisation and Lymphatic Systems Around the Pelvic Floor: A Literature Review.
    Anticancer Res. 2021;41:4705-4714.
    PubMed     Abstract available


  188. IIDA T, Murono K, Shiratori H, Nozawa H, et al
    Impact of Inferior Mesenteric Artery Occlusion on the Calibre of Collateral Arteries of the Colon.
    Anticancer Res. 2021;41:5189-5193.
    PubMed     Abstract available


  189. CHUNG YC, Ku YL, Chiang HC, Liu WC, et al
    Antibody to Interleukin-6 Receptor Inhibits In Vivo Growth of Human Colorectal Carcinoma Cell Xenografts.
    Anticancer Res. 2021;41:4907-4916.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Colorectal Neoplasms is free of charge.